ACUR · As filed with the SEC
Acura Pharmaceuticals cash flow statement, by quarter
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q4 2021 3 months ended Dec 31, 2021 | Q3 2021 3 months ended Sep 30, 2021 | Q2 2021 3 months ended Jun 30, 2021 | Q1 2021 3 months ended Mar 31, 2021 | Q4 2020 3 months ended Dec 31, 2020 | Q3 2020 3 months ended Sep 30, 2020 | Q2 2020 3 months ended Jun 30, 2020 | Q1 2020 3 months ended Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|
| Cash Flows from Operating Activities: | ||||||||
| Net loss | — | — | — | (259,000) | — | — | — | (595,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | — | — | — | 11,000 | — | — | — | 15,000 |
| Non-cash stock-based compensation | — | — | — | 0 | — | — | — | 9,000 |
| Amortization of intangible asset | — | — | — | 7,000 | — | — | — | 51,000 |
| Impairment charge on intangible asset | — | — | — | 0 | — | — | — | 668,000 |
| Changes in assets and liabilities: | ||||||||
| Royalty receivable | — | — | — | 0 | — | — | — | 52,000 |
| Collaboration revenue receivable from related party | — | — | — | 93,000 | — | — | — | 73,000 |
| License fee receivable from related party | — | — | — | (400,000) | — | — | — | — |
| Prepaid expenses and other current assets | — | — | — | 55,000 | — | — | — | 47,000 |
| Accounts payable | — | — | — | 34,000 | — | — | — | (129,000) |
| Accrued expenses | — | — | — | 33,000 | — | — | — | 46,000 |
| Accrued interest on related party loans | — | — | — | 113,000 | — | — | — | 112,000 |
| Other current liabilities | — | — | — | 0 | — | — | — | (2,000) |
| Net cash used in operating activities | — | — | — | (313,000) | — | — | — | 347,000 |
| Cash Flows from Financing Activities: | ||||||||
| Proceeds from distribution of RSU awards | — | — | — | 3,000 | — | — | — | 3,000 |
| Statutory minimum payroll withholding taxes paid on the distribution of shares pursuant to RSU awards | — | — | — | (8,000) | — | — | — | (2,000) |
| Proceeds from loan under CARES Act | — | — | — | 266,000 | — | — | — | — |
| Net cash provided by financing activities | — | — | — | 261,000 | — | — | — | 1,000 |
| Net decrease in cash | — | — | — | (52,000) | — | — | — | 348,000 |
| Cash at beginning of period | 89,000 | 167,000 | 361,000 | 413,000 | 493,000 | 1,038,000 | 1,210,000 | 862,000 |
| Cash at end of end of period | 65,000 | 89,000 | 167,000 | 361,000 | 413,000 | 493,000 | 1,038,000 | 1,210,000 |
| Supplemental Disclosures of Cash Flow Information: | ||||||||
| Cash interest payments on loans | — | — | — | 0 | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.